FILING ANALYSIS · THURSDAY, OCTOBER 29
EXELIXIS, INC. EXEL — 8-K: Results of Operations and Financial Condition
positive
Exelixis reported Q3 2026 financial results with total revenues of $658.7 million, beating the comparable period in 2025, and GAAP diluted EPS of $0.85, also exceeding the previous year's result. The company's cabozantinib franchise U.S. net product revenues were $604.9 million, driving the revenue increase.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →